

# 2016 International Clinical Trials Day

## Clinical trials in the era of personalised medicine

20 May 2016

Senate of the Parliament of the Czech Republic, Valdštejnské náměstí 17/4, Gate C2, Praha 1

### Introduction:

The 2016 celebration of International Clinical Trials Day aims to increase awareness of the European Clinical Research Infrastructure Network (ECRIN) and its Czech national scientific partner – Czech Clinical Research Infrastructure Network (CZECRIN) – among Czech policymakers and the scientific community, as well as to address issues related to personalised medicine and multinational clinical trials.

Held under the auspices of Milan Štěch, the President of the Senate of the Parliament of the Czech Republic, the event is organised by ECRIN and CZECRIN in cooperation with the Czech Committee on Health and Social Policy.

Time:	Description:	Who:
8:00 – 8:30	Coffee/Registration	
	<b>ECRIN and medical research infrastructures in the Czech Republic and Europe</b>	<b>Co-Chairs:</b> Rostislav Vyzula, Chairman of the Committee on Health Care (Czech Republic); Regina Demlová, CZECRIN Scientific Partner and Head of Pharmacology, Masaryk University (Czech Republic); Marián Hajdúch, Director of BioMedReg (Czech Republic)
8:30 – 8:40	Welcome address	Jan Zaloudik, Chairman of the Committee on Health and Social Policy (Czech Republic)
8:40 – 8:50	Research infrastructures in the Czech Republic	Robert Plaga, Deputy Minister, Ministry of Education, Youth and Sports (Czech Republic)

8:50 – 9:00	Clinical trials as a part of clinical research in the Czech Republic	Radek Policar, Deputy Minister, Ministry of Health (Czech Republic)
9:00 – 9:05	Discussion	
9:05 – 9:15	Introduction to ECRIN, the instrument for multinational trials in Europe	Jacques Demotes, Director General, ECRIN (France)
9:15 – 9:25	CZECRIN, the Czech national partner of ECRIN	Regina Demlová, CZECRIN Scientific Partner and Head of Pharmacology, Masaryk University (Czech Republic)
9:25 – 9:30	Discussion	
9:30 – 9:40	Clinical component of ESFRI infrastructures: current issues and future challenges	Dalibor Valík, Head of the Department of Laboratory Medicine and Managing Director of the Regional Centre for Applied Medical Oncology (RECAMO), Masaryk Memorial Cancer Institute (Czech Republic)
9:40 – 9:55	Clinical trials in the Czech Republic from an industry perspective	Jakub Dvořáček, CEO of Association of Innovative Pharmaceutical Industry (AIFP) (Czech Republic)
9:55 – 10:10	Discussion	
10:10 – 10:40	Coffee	
	<b>Personalised medicine: definition, case study</b>	<b>Co-chairs:</b> Silvio Garattini, Director, Istituto di Ricerche Farmacologiche Mario Negri (IRCCS) (Italy); Christian Gluud, Head of Department, Copenhagen Trial Unit, Centre for Clinical Intervention Research (Denmark)
10:40 – 11:00	What is personalised medicine? Use and meaning of the term	Anna Pokorska-Bocci, Senior Scientific Officer, Personalised Medicine, Debiopharm International SA (United Kingdom)
11:05 – 11:25	Personalised medicine and evidence-based medicine	Dhavendra Kumar, Consultant in Clinical Genetics, Institute of Cancer & Genetics, Cardiff University School of Medicine (United Kingdom)
11:30 – 11:50	Development of personalised medicine within child oncology: a case study	Norbert Graf, Professor of Paediatrics and Head of Paediatric Oncology, Saarland University (Germany)

	<b>Personalised medicine: methodological, ethical and regulatory aspects</b>	<b>Co-chairs:</b> Jaroslav Štěrba, Vice-Dean, Faculty of Medicine, Masaryk University (Czech Republic); Christian Gluud
11:55 – 12:15	Methodological aspects and challenges of personalised medicine	Ian Roberts, Professor of Epidemiology and Public Health and Co-director of the Clinical Trials Unit at the London School of Hygiene & Tropical Medicine (LSHTM) (United Kingdom)
12:20 – 12:40	Ethical aspects of personalised medicine	Nicole Nelson, Assistant Professor, Department of History of Science, University of Wisconsin – Madison (United States)
12:45 – 13:05	Regulatory challenges and views on personalised medicine	Marisa Papaluca, Senior Scientific Advisor, European Medicines Agency (EMA) (United Kingdom)
13:10 – 14:10	Lunch	
	<b>Personalised medicine: scientific, industry and patient perspectives</b>	<b>Co-chairs:</b> Gonzalo Calvo, Senior Consultant at Hospital Clinic Barcelona and Associate Professor of Clinical Pharmacology, University of Barcelona (Spain); Christian Gluud
14:10 – 14:30	Personalised medicine from a scientific perspective	Paraskevi Katsaounou, Assistant Professor of Pulmonary Medicine, University of Athens Medical School, Evaggelismos Hospital (Greece)
14:35 – 14:55	Personalised medicine from a multi-stakeholder perspective	Denis Horgan, Executive Director, European Alliance for Personalised Medicine (Belgium)
15:00 – 15:20	Personalised medicine from an industry perspective	Magda Chlebus, Director of Science Policy at the European Federation of Pharmaceutical Industries and Associations (EFPIA) (Belgium)
	<b>Panel discussion</b>	<b>Chair:</b> Christian Gluud
15:25 – 15:45	What is the future of clinical trials and evidence-based medicine in the era of personalised medicine?	All chairs and speakers
15:45 – 15:50	Conclusion	Jacques Demotes



Follow @ECRIN\_ERIC

Tweet with tags: #ICTD2016